LimFlow
LimFlow is a private, venture-backed medical device company transforming the treatment of Critical Limb Ischemia, a growing clinical need in the face of the prevalence of diabetes, heart disease and an aging population. The LimFlow Percutaneous Deep Vein Arterialization (pDVA) System is designed to bypass blocked arteries in the leg and rush oxygenated blood back into the foot. For many patients, restoring perfusion in the lower limbs resolves chronic pain, improves quality of life, promotes wound healing and prevents major amputation.
Sector
Medical Devices
Strategies
MD Start & Crossover
Status
Exit
Website
limflow.com
Kinam Hong
Partner, Sofinnova Partners - Crossover Strategy
Anne Osdoit
Partner, Sofinnova Partners - MD Start Strategy
Related News
LimFlow announces agreement to be acquired by Inari Medical
Landmark New England Journal of Medicine publication reports positive results from PROMISE II pivotal trial showing that LimFlow System saves most patients with end-stage peripheral artery disease from major amputation
LimFlow raises $40 million (€36 million) in Series D financing
Limflow raises €27 million ($33.5 million) in Series C financing led by Sofinnova Partners to advance innovative critical limb ischemia (CLI) treatment
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.